Dermata Therapeutics Inc (DRMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dermata Therapeutics Inc (DRMA) has a cash flow conversion efficiency ratio of -0.455x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.80 Million) by net assets ($3.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Dermata Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Dermata Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Dermata Therapeutics Inc (DRMA) total liabilities for a breakdown of total debt and financial obligations.
Dermata Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dermata Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alliance Pharma plc
LSE:APH
|
0.099x |
|
Horus AG
STU:HRU
|
N/A |
|
CASI Pharmaceuticals Inc
NASDAQ:CASI
|
0.029x |
|
Vault Strategic Mining Corp.
V:KNOX
|
0.054x |
|
Yunnan Water Investment Co. Limited
F:2WI
|
-0.010x |
|
Altur Slatina
RO:ALT
|
N/A |
|
PREMIER AFRICAN MINERALS
F:0PA
|
N/A |
|
Kuke Music Holding Ltd
NYSE:KUKE
|
-0.498x |
Annual Cash Flow Conversion Efficiency for Dermata Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Dermata Therapeutics Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see DRMA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.56 Million | $-11.16 Million | -7.151x | -609.06% |
| 2023-12-31 | $6.36 Million | $-6.41 Million | -1.008x | +31.26% |
| 2022-12-31 | $6.02 Million | $-8.83 Million | -1.467x | -160.43% |
| 2021-12-31 | $10.11 Million | $-5.69 Million | -0.563x | -144.44% |
| 2020-12-31 | $-3.18 Million | $-4.03 Million | 1.268x | -93.21% |
| 2019-12-31 | $-210.16K | $-3.92 Million | 18.663x | -- |
About Dermata Therapeutics Inc
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept… Read more